Literature DB >> 11251569

Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.

J I Ross1, A M Snelling, E A Eady, J H Cove, W J Cunliffe, J J Leyden, P Collignon, B Dréno, A Reynaud, J Fluhr, S Oshima.   

Abstract

BACKGROUND: Propionibacterium acnes is the target of antimicrobial treatments for acne vulgaris. Acquired resistance to erythromycin, clindamycin and tetracyclines has been reported in strains from diverse geographical loci, but the molecular basis of resistance, via mutations in genes encoding 23S and 16S rRNA, respectively, has so far only been elucidated for isolates from the U.K.
OBJECTIVES: To determine whether similar or different resistance mechanisms occur in resistant P. acnes isolates from outside the U.K.
METHODS: The phenotypes and genotypes of 73 antibiotic-resistant strains of P. acnes obtained from the skin of acne patients in the U.K., U.S.A., France, Germany, Australia and Japan were compared. Antibiotic susceptibilities were determined by minimum inhibitory concentration (MIC) measurements, and polymerase chain reaction and DNA sequencing were used to identify mutations in genes encoding rRNA.
RESULTS: Most erythromycin-resistant isolates (MIC(90) > or = 512 microg mL(-1)) were cross-resistant to clindamycin but at a much lower level (MIC(90) > or = 64 microg mL(-1)). As in the U.K., resistance to erythromycin was associated with point mutations in 23S rRNA in 49 of 58 strains. An A-->G transition at Escherichia coli equivalent base 2058 was present in 24 strains. This gave a unique cross-resistance phenotype against a panel of macrolide, lincosamide and type B streptogramin antibiotics. Two further point mutations (at E. coli equivalent bases 2057 and 2059) were identified (in three and 22 isolates, respectively) and these were also associated with specific cross-resistance patterns originally identified in isolates from the U.K. However, nine of 10 erythromycin resistant-strains from Germany did not exhibit any of the three base mutations identified and, in six cases, cross-resistance patterns were atypical. Consistent with previous U.K. data, 34 of 38 tetracycline-resistant strains carried a base mutation at E. coli 16S rRNA equivalent base 1058. Tetracycline-resistant isolates displayed varying degrees of cross-resistance to doxycycline and minocycline, but isolates from the U.S.A. had higher MICs for minocycline (4--16 microg mL(-1)) than isolates from other countries and, in particular, Australia. All the P. acnes isolates resistant to one or more of the commonly used antiacne antibiotics were sensitive to penicillin, fusidic acid, chloramphenicol and the fluoroquinolone, nadifloxacin. All but one isolate (from the U.K.) were sensitive to trimethoprim.
CONCLUSIONS: This study shows that 23S and 16S mutations identified in the U.K. conferring antibiotic resistance in P. acnes are distributed widely. However, resistant strains were isolated in which mutations could not be identified, suggesting that as yet uncharacterized resistance mechanisms have evolved. This is the first report of high-level resistance to minocycline and is of concern as these strains are predicted to be clinically resistant and are unlikely to remain confined to the U.S.A. Epidemiological studies are urgently required to monitor how resistant strains are selected, how they spread and to ascertain whether the prevalence of resistance correlates with antibiotic usage patterns in the different countries.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251569     DOI: 10.1046/j.1365-2133.2001.03956.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  30 in total

Review 1.  Acne: more than skin deep.

Authors:  J Ayer; N Burrows
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

2.  Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic.

Authors:  Stefanie Heller; Laurenz Kellenberger; Stuart Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

3.  Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori.

Authors:  Emiko Rimbara; Norihisa Noguchi; Takashi Kawai; Masanori Sasatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

4.  Chronic administration of oral trimethoprim-sulfamethoxazole for acne vulgaris.

Authors:  Morgan McCarty; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-08

Review 5.  Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Authors:  Yvonne Achermann; Ellie J C Goldstein; Tom Coenye; Mark E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

6.  Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use.

Authors:  James Q Del Rosso; Guy F Webster; Ted Rosen; Diane Thiboutot; James J Leyden; Richard Gallo; Clay Walker; George Zhanel; Lawrence Eichenfield
Journal:  J Clin Aesthet Dermatol       Date:  2016-04-01

Review 7.  Topical antibacterial therapy for acne vulgaris.

Authors:  Brigitte Dreno
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Bacterial resistance to antibiotics in acne vulgaris: an in vitro study.

Authors:  Parvin Hassanzadeh; M Bahmani; Davood Mehrabani
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

Review 9.  Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics.

Authors:  Marilyn C Roberts
Journal:  Mol Biotechnol       Date:  2004-09       Impact factor: 2.695

10.  Activity of the novel macrolide BAL19403 against ribosomes from erythromycin-resistant Propionibacterium acnes.

Authors:  Jürg Dreier; Eva Amantea; Laurenz Kellenberger; Malcolm G P Page
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.